Could coenzyme Q10 affect hemostasis by inhibiting platelet vitronectin (CD51/CD61) receptor?

Area of Science:

• Cardiovascular Research
• Nutritional Science
• Hematology

Background:

• Dietary coenzyme Q10 (CoQ10) supplementation is linked to improved cardiovascular outcomes.
• Proposed mechanisms include CoQ10's potential to inhibit platelet activity.
• Understanding CoQ10's impact on hemostasis is crucial for explaining its clinical benefits.

Purpose of the Study:

• To investigate the effects of CoQ10 intake on platelet surface antigens and hemostatic parameters.
• To determine if CoQ10 influences key factors involved in blood clotting and platelet function.

Main Methods:

• 15 human and 10 swine participants received 100 mg CoQ10 twice daily for 20 days.
• Serum CoQ10 levels were monitored, showing a threefold increase.
• Plasma levels of fibronectin, thromboxane B2, prostacyclin, and endothelin-1 were measured.
• Platelet vitronectin receptor expression was assessed.

Main Results:

• CoQ10 supplementation led to significant reductions in plasma fibronectin (-20.2%), thromboxane B2 (-20.6%), prostacyclin (-23.2%), and endothelin-1 (-17.9%).
• A consistent and significant inhibition of platelet vitronectin receptor expression was observed.
• These changes indicate reduced platelet activation and aggregation.

Conclusions:

• Dietary CoQ10 intake directly impacts platelet function and hemostasis.
• Inhibition of the platelet vitronectin receptor by CoQ10 provides a mechanistic link to its cardiovascular benefits.
• These findings support the hypothesis that CoQ10 reduces thrombotic risk, contributing to improved cardiovascular morbidity and mortality.